Menu

Impact Events

More
Date Lead Company Event Type Approval Change Approval Likelihood
9/21/23 Intarcia ITCA 650 for Diabetes Mellitus, Type II Subscribers Only Subscribers Only Subscribers Only
9/19/23 Intarcia ITCA 650 for Diabetes Mellitus, Type II Subscribers Only Subscribers Only Subscribers Only
9/13/23 Alnylam (ALNY) Onpattro for Transthyretin Amyloid Cardiomyopathy (ATTR-CM, Wild Type Or Hereditary) Subscribers Only Subscribers Only Subscribers Only
9/12/23 Humacyte (HUMA) Humacyl for Peripheral Arterial Disease (PAD) Subscribers Only Subscribers Only Subscribers Only
9/12/23 AbbVie (ABBV) Skyrizi for Crohn's Disease Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected Date Range Lead Company Drug Expected Catalyst
09/23/23 Subscribers Only Subscribers Only Trial Announcement - Initiation
09/23/23 Subscribers Only Subscribers Only Regulatory - PDUFA/Approval Decision (U.S.)
09/23/23 Subscribers Only Subscribers Only Trial Data - Updated Results
09/23/23 Subscribers Only Subscribers Only Trial Data - Updated Results
09/23/23 Subscribers Only Subscribers Only Trial Data - Updated Results
Back to the top Back to the top